Immune landscape and response to oncolytic virus-based immunotherapy

doi:10.1007/s11684-023-1048-0

Review

. 2024 Jun;18(3):411-429.

doi: 10.1007/s11684-023-1048-0. Epub 2024 Mar 8.

Immune landscape and response to oncolytic virus-based immunotherapy

Chaolong Lin^#^{1

2}, Wenzhong Teng^#^{1

2}, Yang Tian^#^{1

2}, Shaopeng Li^{1

2}, Ningshao Xia^{3

4}, Chenghao Huang^{5

6}

Affiliations

¹ State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China.
² National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, 361102, China.
³ State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. nsxia@xmu.edu.cn.
⁴ National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, 361102, China. nsxia@xmu.edu.cn.
⁵ State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. huangchenghao@xmu.edu.cn.
⁶ National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, 361102, China. huangchenghao@xmu.edu.cn.

^# Contributed equally.

PMID: 38453818
DOI: 10.1007/s11684-023-1048-0

Review

Immune landscape and response to oncolytic virus-based immunotherapy

Chaolong Lin et al. Front Med. 2024 Jun.

. 2024 Jun;18(3):411-429.

doi: 10.1007/s11684-023-1048-0. Epub 2024 Mar 8.

Authors

Chaolong Lin^#^{1

2}, Wenzhong Teng^#^{1

2}, Yang Tian^#^{1

2}, Shaopeng Li^{1

2}, Ningshao Xia^{3

4}, Chenghao Huang^{5

6}

Affiliations

¹ State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China.
² National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, 361102, China.
³ State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. nsxia@xmu.edu.cn.
⁴ National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, 361102, China. nsxia@xmu.edu.cn.
⁵ State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China. huangchenghao@xmu.edu.cn.
⁶ National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen, 361102, China. huangchenghao@xmu.edu.cn.

^# Contributed equally.

PMID: 38453818
DOI: 10.1007/s11684-023-1048-0

Abstract

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues. However, the immunosuppressive nature of tumor microenvironment (TME) poses a substantial hurdle to the development of OVs as effective immunotherapeutic agents, as it restricts the activation and recruitment of immune cells. This review elucidates the potential of OV-based immunotherapy in modulating the immune landscape within the TME to overcome immune resistance and enhance antitumor immune responses. We examine the role of OVs in targeting specific immune cell populations, including dendritic cells, T cells, natural killer cells, and macrophages, and their ability to alter the TME by inhibiting angiogenesis and reducing tumor fibrosis. Additionally, we explore strategies to optimize OV-based drug delivery and improve the efficiency of OV-mediated immunotherapy. In conclusion, this review offers a concise and comprehensive synopsis of the current status and future prospects of OV-based immunotherapy, underscoring its remarkable potential as an effective immunotherapeutic agent for cancer treatment.

Keywords: immune landscape; immunotherapeutic agents; immunotherapy; oncolytic virus.

PubMed Disclaimer

Cited by

Parainfluenza Virus 5 V Protein Blocks Interferon Gamma-Mediated Upregulation of NK Cell Inhibitory Ligands and Improves NK Cell Killing of Neuroblastoma Cells.
Shiffer EM, Oyer JL, Copik AJ, Parks GD. Shiffer EM, et al. Viruses. 2024 Aug 9;16(8):1270. doi: 10.3390/v16081270. Viruses. 2024. PMID: 39205244 Free PMC article.
A Type I IFN-Inducing Oncolytic Virus Improves NK Cell-Mediated Killing of Tumor Cells In Vitro Through Multiple Mechanisms.
Shiffer EM, Oyer JL, Copik AJ, Parks GD. Shiffer EM, et al. Viruses. 2025 Jun 25;17(7):897. doi: 10.3390/v17070897. Viruses. 2025. PMID: 40733515 Free PMC article.
Murine colon cancer derived cells exhibit heterogeneous resistance profiles against an oncolytic virus.
Larrieux A, Sanjuán R. Larrieux A, et al. Sci Rep. 2024 Nov 8;14(1):27209. doi: 10.1038/s41598-024-78313-6. Sci Rep. 2024. PMID: 39516525 Free PMC article.
Immunological Impact of Oncolytic Adenoviruses On Cancer Therapy: Clinical Insights.
Nadafi R, Dong W, van Beusechem VW. Nadafi R, et al. Eur J Immunol. 2025 Jul;55(7):e70024. doi: 10.1002/eji.70024. Eur J Immunol. 2025. PMID: 40726054 Free PMC article. Review.

References

1. Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers (Basel) 2021; 13(6): 1383 - PubMed - DOI
1. Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M. Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 2022; 28(8): 1630–1639 - PubMed - PMC - DOI
1. Qiao Q, Song M, Song C, Zhang Y, Wang X, Huang Q, Wang B, Yang P, Zhao S, Li Y, Wang Z, Zhao J. Single-dose vaccination of recombinant chimeric newcastle disease virus (NDV) LaSota vaccine strain expressing infectious bursal disease virus (IBDV) VP2 gene provides full protection against genotype VII NDV and IBDV challenge. Vaccines (Basel) 2021; 9(12): 1483 - PubMed - DOI
1. Vijayakumar G, Palese P, Goff PH. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine 2019; 49: 96–105 - PubMed - PMC - DOI
1. Huang Z, Liu M, Huang Y. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus. Discov Med 2020; 30(159): 39–48 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information

[1] Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers (Basel) 2021; 13(6): 1383 - PubMed - DOI

[2] Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers (Basel) 2021; 13(6): 1383 - PubMed - DOI

[3] Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M. Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 2022; 28(8): 1630–1639 - PubMed - PMC - DOI

[4] Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M. Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 2022; 28(8): 1630–1639 - PubMed - PMC - DOI

[5] Qiao Q, Song M, Song C, Zhang Y, Wang X, Huang Q, Wang B, Yang P, Zhao S, Li Y, Wang Z, Zhao J. Single-dose vaccination of recombinant chimeric newcastle disease virus (NDV) LaSota vaccine strain expressing infectious bursal disease virus (IBDV) VP2 gene provides full protection against genotype VII NDV and IBDV challenge. Vaccines (Basel) 2021; 9(12): 1483 - PubMed - DOI

[6] Qiao Q, Song M, Song C, Zhang Y, Wang X, Huang Q, Wang B, Yang P, Zhao S, Li Y, Wang Z, Zhao J. Single-dose vaccination of recombinant chimeric newcastle disease virus (NDV) LaSota vaccine strain expressing infectious bursal disease virus (IBDV) VP2 gene provides full protection against genotype VII NDV and IBDV challenge. Vaccines (Basel) 2021; 9(12): 1483 - PubMed - DOI

[7] Vijayakumar G, Palese P, Goff PH. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine 2019; 49: 96–105 - PubMed - PMC - DOI

[8] Vijayakumar G, Palese P, Goff PH. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine 2019; 49: 96–105 - PubMed - PMC - DOI

[9] Huang Z, Liu M, Huang Y. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus. Discov Med 2020; 30(159): 39–48 - PubMed

[10] Huang Z, Liu M, Huang Y. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus. Discov Med 2020; 30(159): 39–48 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immune landscape and response to oncolytic virus-based immunotherapy

Affiliations

Immune landscape and response to oncolytic virus-based immunotherapy

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Medical